Sfoglia per AUTORE
ZATTARIN E
Collezione AO Ordine Mauriziano
Items : 4
Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21). in Expert review of anticancer therapy / Expert Rev Anticancer Ther. 2022 Jan;22(1):115-121. doi: 10.1080/14737140.2022.2002688. Epub 2021 No
2022
AO Ordine Mauriziano
AOU San Luigi di Orbassano
Procopio G; Verzoni E; De Braud FG; Pignata S; Ottini A; Guadalupi V; Claps M; Sepe P; Stellato M; Buttigliero C; Roviello G; Di Lorenzo G; Mucciarini C; Messina C; Sorarù M; Santini D; Casadei C; Buti S; De Giorgi U; Mennitto A; Zattarin E; Di Maio M; Bimbatti D;
Erratum to 'Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario': [ESMO Open Volume 7, Issue 2, April 2022, 100406]. in ESMO open / ESMO Open. 2022 Apr;7(2):100471. doi: 10.1016/j.esmoop.2022.100471. Epub 2022 Apr 1.
2022
AO Ordine Mauriziano
Cantini L; Mentrasti G; Lo Russo G; Signorelli D; Pasello G; Rijavec E; Russano M; Antonuzzo L; Rocco D; Giusti R; Adamo V; Genova C; Tuzi A; Morabito A; Gori S; La Verde N; Chiari R; Cortellini A; Cognigni V; Pecci F; Indini A; De Toma A; Zattarin E; Oresti S; Pizzutilo EG; Frega S; Erbetta E; Galletti A; Citarella F; et alii...
Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario. in ESMO open / ESMO Open. 2022 Apr;7(2):100406. doi: 10.1016/j.esmoop.2022.100406. Epub 2022 Feb 3.
2022
AO Ordine Mauriziano
Cantini L; Mentrasti G; Russo GL; Signorelli D; Pasello G; Rijavec E; Russano M; Antonuzzo L; Rocco D; Giusti R; Adamo V; Genova C; Tuzi A; Morabito A; Gori S; Verde N; Chiari R; Cortellini A; Cognigni V; Pecci F; Indini A; De Toma A; Zattarin E; Oresti S; Pizzutilo EG; Frega S; Erbetta E; Galletti A; Citarella F; et alii...
Prospective Translational Study Investigating Molecular PrEdictors of Resistance to First-Line PazopanIb in Metastatic reNal CEll Carcinoma (PIPELINE Study). in American journal of clinical oncology / Am J Clin Oncol. 2020 Sep;43(9):621-627. doi: 10.1097/COC.0000000000000719.
2020
AO Ordine Mauriziano
Sepe P; Martinetti A; Mennitto A; Verzoni E; Claps M; Raimondi A; Sottotetti E; Grassi P; Guadalupi V; Stellato M; Zattarin E; Di Maio M; Procopio G;